Table 6.
Univariate analysis of risk factors for neuropathic pain features in study patients
| Factors | Non-neuropathic group (n = 92) | Neuropathic group (n = 41) | Total (n = 133) | P value |
|---|---|---|---|---|
| Age (yr) | 60.57 ± 10.88 | 55.76 ± 12.38 | 59.08 ± 11.53 | 0.026 |
| Female | 51 (55.4) | 23 (56.1) | 74 (55.6) | 0.943 |
| Primary cancer site | ||||
| Lung | 25 (27.2) | 10 (24.4) | 35 (26.3) | 0.175 |
| Breast | 21 (22.8) | 12 (29.3) | 33 (24.8) | |
| Prostate | 11 (12.0) | 0 (0.0) | 11 (8.3) | |
| Head and neck | 8 (8.7) | 3 (7.3) | 11 (8.3) | |
| Others | 27 (29.3) | 16 (39.0) | 43 (32.3) | |
| Number of sites of bone metastasis | ||||
| 1 | 11 (12.0) | 7 (17.1) | 18 (13.5) | 0.205 |
| 2 | 17 (18.5) | 12 (29.3) | 29 (21.8) | |
| ≥ 3 | 64 (69.6) | 22 (53.7) | 86 (64.7) | |
| Dominant site of bone pain | ||||
| Pelvis | 30 (32.6) | 14 (34.1) | 44 (33.1) | 0.030 |
| Spine | 29 (31.5) | 6 (14.6) | 35 (26.3) | |
| Chest wall | 25 (27.2) | 10 (24.4) | 35 (26.3) | |
| Extremities | 6 (6.5) | 10 (24.4) | 16 (12.0) | |
| Skull | 2 (2.2) | 1 (2.4) | 3 (2.3) | |
| Fracture | 13 (14.1) | 4 (9.8) | 17 (12.8) | 0.485 |
| Average pain | 5.05 ± 1.75 | 6.00 ± 1.88 | 5.35 ± 1.84 | 0.006 |
| Time from diagnosis of cancer to evaluation (mo) | 19.47 (5.89, 50.93) | 28.00 (4.20, 56.87) | 20.30 (5.65, 53.70) | 0.465 |
| Time from diagnosis of bone metastasis to evaluation (mo) | 2.93 (0.65, 9.05) | 2.57 (1.12, 20.25) | 2.73 (0.75, 10.17) | 0.474 |
| Morphine milligram equivalent | 25.00 (15.63, 40.00) | 30.00 (20.00, 55.50) | 28.00 (18.75, 40.00) | 0.033 |
| Previous chemotherapy | 67 (72.8) | 29 (70.7) | 96 (72.2) | 0.803 |
| Previous radiation therapy | 26 (28.3) | 12 (29.3) | 38 (28.6) | 0.905 |
| Previous surgery | 4 (4.3) | 3 (7.3) | 7 (5.3) | 0.676 |
Values are presented as mean ± standard deviation, number (%), or median (P25, P75).
P25: percentile 25, P75: percentile 75.